Obesity

In part 3 of this Exclusive Interview, Blandine Lacroix talks about applying motivational interviewing in the patient/provider conversation around diabetes.

In a new international clinical trial, it was shown that the drug liraglutide 3.0 mg may reduce diabetes risk by 80% in individuals with obesity and prediabetes.

In part 2 of this Exclusive Interview, Blandine Lacroix shares the tools that Novo Nordisk provides to help practitioners as well as patients with the disease of obesity, including websites that share the science of obesity and weight loss.

Blandine Lacroix talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 1 of this Exclusive Interview, Blandine Lacroix explains the focus of Novo Nordisk on understanding how to improve the care of obesity in the search for the cure for diabetes.

Woman, 63 years of age, history of ovarian cancer, prediabetes, hyperlipidemia, has been trying to lose weight for years but was unable to do so. She is very family-, friend-, colleague-oriented. Every holiday she thought she had to make or bring and eat whatever special holiday food was associated with the holiday. She couldn’t let anyone down by not bringing, or by not eating what other people brought. We met weekly for the past three years. Every week there was some excuse about how or why she “cheated” or if there was a week she didn’t think she “cheated,” then she was afraid she would.

Early initiation of therapy hoped to reduce long-term morbidity, mortality by getting to goal earlier; potentially alter the natural history of the disease.

The use of a high protein diet instead of a high carbohydrate diet to help reverse the progression to diabetes.

Sucralose may adversely affect glucose metabolism.

Two products approved by FDA will be available in 2017.

New study finds that when you lose weight, you will consume more calories than necessary to maintain the lower weight.